1. Scrip
  2. >>R&D

Vaccinex Sees Mixed Signals In Huntington’s Study

Pepinemab Missed Key Endpoints In Phase II Trial

 
• By Joseph Haas

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Hand flip wooden cube with the word PLAN A to PLAN B on white background. Business concept
With mixed data in Huntington's, Vaccinex turns attention to Alzheimer's

Vaccinex, Inc.’s potentially disease-modifying therapy for Huntington’s disease missed its key endpoints in top-line data unveiled 22 September from the Phase II SIGNAL study, but the biotech thinks the novel drug offers potential in both Alzheimer’s disease and also later-stage Huntington’s patients than those included in the trial.

The company noted that in cohort B1 of SIGNAL – testing the semaphorin 4D (SEMA4D) inhibitor pepinemab in 179 early manifest Huntington’s patients – it saw trends towards improvement in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D